saw103

Scott A. Waldman, MD, PhD

Contact Dr. Waldman

1020 Locust Street
368 JAH
Philadelphia, PA 19107

(215) 955-6086
(215) 955-7006 fax

Most Recent Peer-reviewed Publications

  1. Emerging targets for the diagnosis of Parkinson's disease: Examination of systemic biomarkers
  2. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders
  3. Stem cells as therapeutic targets in colorectal cancer
  4. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies
  5. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
  6. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential
  7. The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission
  8. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer
  9. From leptin to lasers: the past and present of mouse models of obesity
  10. Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes
  11. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer
  12. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity
  13. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
  14. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis
  15. Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin
  16. Therapeutic targeting of gastrointestinal cancer stem cells
  17. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia
  18. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
  19. TcR retrogenic mice as a model to map self-tolerance mechanisms to the cancer mucosa antigen GUCY2C
  20. NHERF3 is necessary for Escherichia coli heat-stable enterotoxin-induced inhibition of NHE3: Differences in signaling in mouse small intestine and Caco-2 cells
  21. Blunted evoked prouroguanylin endocrine secretion in chronic constipation
  22. Health Care Evolves From Reactive to Proactive
  23. Myeloid-specific deletion of Zfp36 protects against insulin resistance and fatty liver in diet-induced obese mice
  24. Modeling qRT-PCR dynamics with application to cancer biomarker quantification
  25. The guanylate cyclase C-cGMP signaling axis opposes intestinal epithelial injury and neoplasia